Home > Employee Benefits, Property & Casualty > Insurer steps into drug pricing controversy

Insurer steps into drug pricing controversy

lawsuitInsurance will play a huge role in the developing drug pricing controversy.  Healthcare commentator, Ezekial Emanual, opined in yesterday’s New York Times that new drugs, particularly PCSK9 inhibitors for cholesterol control, are entering the market at prices well above their utility as measured by the extremely clinical, but widely used,  “Quality-adjusted Life Years” measure.  Now, of course, Amgen (a PCSK9 maker) may not agree with Emanuel’s calculations and that represents just one of the problems.

Emanuel fairly raises the question of whether the drug/healthcare industry will self-regulate the issue.  The alternative, “death panels” from the government, are highly unlikely based on prior debates. 

Some answers to his question are found in today’s Boston Globe.  At the macro level, the national drug trade organization, PhRMA, seems to be backing away from overly aggressive pricing strategies like the highly reported efforts of Turing and Valeant.  That suggests that the industry is willing to draw lines in order to protect itself from regulation.

Closer to the Boston Globe’s home, insurer Harvard Pilgrim Health Care (HPHC) is reported to have inked a deal with Amgen for a risk-sharing model of pricing based on performance.

Pharmaceutical companies, and particularly young biotechnology companies face a large risk in this battle.  One justification for high prices of new drugs is the need to reward risk-taking shareholders of young drug companies.  HPHC and Amgen seem to be working toward a version of that dynamic pricing model with risk shared by insurer, payer (business/consumer both) and the drug company.  Perhaps this is the best answer we can find right now and it surely is a development well worth watching closely.


About the Author

Phil Edmundson is the Area Chairman of Gallagher WGA with over 30 years in the insurance industry. He manages innovation, strategy, talent acquisition and development for this leading insurance brokerage.

617.646.0229 | Phil_Edmundson@ajg.comConnect with Phil on LinkedIn |
Follow Phil @PhilEdmundson
MORE POSTS BY PHIL >

  1. No comments yet.
  1. No trackbacks yet.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s